Mark Souder, MD
Family Medicine · Auburn, INNPI 1245218973
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,716 of the $24,326 with a category attached, or 89.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $6,180 and has fallen 50.6% since, to $3,050 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,098 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$2K
- GSK$2K
- Supernus Pharmaceuticals, Inc.$1K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $11K from 54 others
What the payments were for
- Speaking & faculty fees$2,50010%
- Food & beverage$21,71689%
- Education$600%
- Other$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$2,610
- Ozempic$485
- Kerendia$484
- QELBREE$427
- BREZTRI$388
- AIRSUPRA$377
- AREXVY$363
- ABILIFY MAINTENA$246
- FARXIGA$245
- REXULTI$228
- EVENITY$227
- VRAYLAR$225
- Auvelity$211
- ABILIFY ASIMTUFII$124
- NUEDEXTA$124
- Jornay PM 20mg capsules (Bottle of 100)$123
- JARDIANCE$121
- Azstarys$121
- TRELEGY ELLIPTA$121
- Xultophy 100/3.6$121
How this compares
$24,326 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 133 | $156,215 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $96,289 |
| OzempicSemaglutide | 74 | $94,025 |
| FarxigaDapagliflozin Propanediol | 86 | $93,796 |
| JardianceEmpagliflozin | 72 | $92,007 |
| XareltoRivaroxaban | 69 | $74,544 |
| MounjaroTirzepatide | 42 | $57,793 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $32,707 |
| VraylarCariprazine Hcl | 12 | $19,232 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $18,658 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $17,300 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $15,968 |
| TrulicityDulaglutide | 14 | $15,791 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,520 |
| RybelsusSemaglutide | 14 | $13,285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $778 | $158,698144 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,603 | $127,109122 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $2,113 | $111,190129 claims |
| Novo NordiskOzempic, Rybelsus | $1,042 | $107,30988 claims |
| Boehringer IngelheimJardiance | $428 | $92,00772 claims |
| Johnson & JohnsonXarelto | $177 | $74,54469 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,191 | $73,58456 claims |
| AbbVieVraylar | $5,303 | $19,23212 claims |
| MerckJanuvia | $63 | $12,54314 claims |
| BayerKerendia | $909 | $11,87611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $324 | $4,28211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Auburn
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.